Nimotuzumab as Additional Therapy for GLIOMA in Pediatric and Adolescent: A Systematic Review.

Cancer Control · 2022 · PMC8874160 · PMID 35191733

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

41 , 42 A clear trend toward a benefit from nimotuzumab therapy was also detectable in that whole study cohort using activation of mTORC1 as a marker for dichotomy.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.